Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tbo-filgrastim in Pediatric Solid Tumors
NCT02190721Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2015
- Primary completion
- Apr 2017
- Modality
- Cytokines & Interferons
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of tbo-filgrastim in neutropenia, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Participants With Adverse Events (AEs), Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results at Day 21 and 7 more. Started May 2015; status: completed.
02
Drugs
tbo-filgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02190721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02190721.